Biopharma Cred. Regulatory News (BPCR)

21 JULY 2020

BioPharma Credit plc

(the "Company")

AMICUS PRepayment

Pharmakon Advisors, the Investment Manager of BioPharma Credit PLC (the "Company"), received a notice of prepayment for its $150 million senior secured loan with Amicus Therapeutics, Inc., (NASDAQ: FOLD, "AMICUS"). As a result, the Company is expected to receive on or before 4 August 2020, approximately $156.2 million, comprised of $150 million in principal, $1.2 million in accrued interest and $5.0 million in make-whole amount and prepayment fees. This investment is expected to generate an IRR of 13.3% as a result of the prepayment.

The Company continues to note a highly supportive environment for its investment strategy and looks forward to updating shareholders on the further deployment of funds.

Enquiries

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 509

J.P. Morgan Cazenove

+44 (0)20 7742 4000

William Simmonds

Oliver Kenyon

Buchanan

+44 (0)20 7466 5000 / biopharmacredit@buchanan.uk.com

David Rydell

Mark Court

Jamie Hooper

Henry Wilson

Notes to Editors

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24